<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: The purpose of this study was to determine the effects of transcatheter <z:hpo ids='HP_0001655'>patent foramen ovale</z:hpo> (<z:mp ids='MP_0004225'>PFO</z:mp>) closure on <z:hpo ids='HP_0002076'>migraine</z:hpo> frequency in patients with paradoxical <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>BACKGROUND: The prevalence of <z:hpo ids='HP_0002076'>migraine headache</z:hpo> is higher in cryptogenic <z:hpo ids='HP_0001297'>stroke</z:hpo> patients with <z:mp ids='MP_0004225'>PFO</z:mp> than in the general population </plain></SENT>
<SENT sid="2" pm="."><plain>Previous studies have suggested that closure of the <z:mp ids='MP_0004225'>PFO</z:mp> may reduce migrainous symptoms </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Between April 2001 and December 2003, 162 consecutive patients with paradoxical <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> underwent transcatheter <z:mp ids='MP_0004225'>PFO</z:mp> closure for prevention of recurrent cryptogenic <z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>A one-year retrospective analysis of <z:hpo ids='HP_0002076'>migraine</z:hpo> symptoms before and after <z:mp ids='MP_0004225'>PFO</z:mp> closure was performed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Active <z:hpo ids='HP_0002076'>migraine</z:hpo> was present in 35% (57 of 162) of patients, and 68% (39 of 57) experienced migrainous aura; 50 patients were available for analysis at one year </plain></SENT>
<SENT sid="6" pm="."><plain>Complete resolution of <z:hpo ids='HP_0002076'>migraine</z:hpo> symptoms occurred in 56% (28 of 50) of patients, and 14% (7 of 50) of patients reported a significant (&gt;or=50%) reduction in <z:hpo ids='HP_0002076'>migraine</z:hpo> frequency </plain></SENT>
<SENT sid="7" pm="."><plain>Patients reported an 80% reduction in the mean number of <z:hpo ids='HP_0002076'>migraine</z:hpo> episodes per month after <z:mp ids='MP_0004225'>PFO</z:mp> closure (6.8 +/- 9.6 before closure vs. 1.4 +/- 3.4 after closure, p &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Results were independent of completeness of <z:mp ids='MP_0004225'>PFO</z:mp> closure at one year </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In patients with paradoxical <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e>, <z:hpo ids='HP_0002076'>migraine headaches</z:hpo> are more frequent than in the general population, and transcatheter closure of the <z:mp ids='MP_0004225'>PFO</z:mp> results in complete resolution or marked reduction in frequency of <z:hpo ids='HP_0002076'>migraine headache</z:hpo> </plain></SENT>
</text></document>